Loading...
XNAS
BCYC
Market cap519mUSD
Jul 08, Last price  
7.50USD
1D
4.60%
1Q
9.01%
IPO
-42.53%
Name

Bicycle Therapeutics PLC

Chart & Performance

D1W1MN
No data to show
P/E
P/S
14.71
EPS
Div Yield, %
Shrs. gr., 5y
39.43%
Rev. gr., 5y
20.65%
Revenues
35m
+30.76%
02,060,0007,136,00013,801,00010,390,00011,697,00014,463,00026,976,00035,275,000
Net income
-169m
L-6.44%
-13,510,360-16,259,000-21,846,000-30,608,000-51,010,000-66,819,000-112,717,000-180,664,000-169,031,000
CFO
-165m
L+171.70%
-11,268,275-1,415,000-26,078,000-28,613,000-17,789,000-14,794,000-86,111,000-60,628,000-164,724,000
Earnings
Aug 04, 2025

Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
IPO date
May 23, 2019
Employees
236
Domiciled in
GB
Incorporated in
GB

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
35,275
30.76%
26,976
86.52%
14,463
23.65%
Cost of revenue
245,147
222,795
134,803
Unusual Expense (Income)
NOPBT
(209,872)
(195,819)
(120,340)
NOPBT Margin
Operating Taxes
(4,765)
1,457
(1,524)
Tax Rate
NOPAT
(205,107)
(197,276)
(118,816)
Net income
(169,031)
-6.44%
(180,664)
60.28%
(112,717)
68.69%
Dividends
Dividend yield
Proceeds from repurchase of equity
544,127
249,345
5,703
BB yield
-66.77%
-38.75%
-0.65%
Debt
Debt current
4,876
3,125
Long-term debt
7,980
54,338
55,210
Deferred revenue
110,216
41,455
Other long-term liabilities
92,588
4,579
3,829
Net debt
(871,540)
(467,209)
(280,819)
Cash flow
Cash from operating activities
(164,724)
(60,628)
(86,111)
CAPEX
(1,235)
(2,929)
(18,987)
Cash from investing activities
(1,235)
(2,929)
(18,987)
Cash from financing activities
519,750
250,027
6,692
FCF
(194,612)
(192,192)
(133,795)
Balance
Cash
879,520
526,423
339,154
Long term investments
Excess cash
877,756
525,074
338,431
Stockholders' equity
(679,782)
(512,514)
(330,322)
Invested Capital
1,569,420
1,043,197
690,714
ROIC
ROCE
EV
Common stock shares outstanding
58,208
35,592
29,661
Price
14.00
-22.57%
18.08
-38.92%
29.60
-51.37%
Market cap
814,906
26.63%
643,510
-26.70%
877,956
-42.45%
EV
(56,634)
176,301
597,137
EBITDA
(202,698)
(189,273)
(116,651)
EV/EBITDA
0.28
Interest
1,730
3,263
3,344
Interest/NOPBT